Hormone receptor–positive (HR+), human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer represents a substantial proportion of breast cancer cases globally. Cyclin-dependent ...

Treatment patterns and outcomes in invasive lobular versus ductal breast carcinoma: A real-world analysis. Comparative response rates & BCS rates: NAHT+CDK-4,6 v/s NACT. This is an ASCO Meeting ...

SAN ANTONIO — Adding the CDK 4/6 blocker palbociclib to standard endocrine and antihuman epidermal growth factor receptor 2 (HER2) therapies in metastatic hormone receptor (HR)–positive, HER2-positive ...

US FDA extends PDUFA date and seeks additional data from AstraZeneca’s NDA for camizestrant in combo with a CDK 4/6 inhibitor to treat HR-positive, HER2-negative advanced breast ...

BUFFALO, N.Y. — Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of ...

Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.

Camizestrant with a CDK 4/6 inhibitor significantly improves progression-free survival in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations. The SERENA-6 trial shows camizestrant's ...

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...

Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic ...

Dr Fatima Cardoso, director of the Breast Cancer Unit at Champalimaud Cancer Centre in Lisbon, Portugal, is a leader in a global initiative [2] to improve the care and treatment of persons with ...